53617-36-0

Usage

Uses

Used in Chemical Synthesis:
1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE is used as a reagent and building block in chemical synthesis for its ability to form a wide range of compounds with diverse applications.
Used as an Intermediate:
1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE is used as an intermediate in the synthesis of more complex organic molecules, contributing to the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.
Used as a Catalyst:
1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE is used as an excellent catalyst for many condensation reactions, enhancing the efficiency and selectivity of these processes in various chemical industries.

InChI:InChI=1/C10H21N3/c1-12-6-8-13(9-7-12)10-2-4-11-5-3-10/h10-11H,2-9H2,1H3

Synthetic route

1-(1-benzylpiperidin-4-yl)-4-methylpiperazine → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
	100%
With palladium on activated charcoal; hydrogen In methanol at 20℃; under 3750.38 Torr; for 2h;	74.9%

1-methyl-piperazine (109-01-3) + N-tert-butyloxycarbonylpiperidin-4-one (79099-07-3) → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
With sodium tris(acetoxy)borohydride; acetic acid In dichloromethane at 0 - 20℃; for 16h;	60%
Stage #1: 1-methyl-piperazine; N-tert-butyloxycarbonylpiperidin-4-one With sodium tris(acetoxy)borohydride; acetic acid In dichloromethane at 0 - 20℃; for 16h; Stage #2: With hydrogenchloride In methanol at 40℃; for 12h;	60%
Multi-step reaction with 2 steps 1: acetic acid; sodium tris(acetoxy)borohydride / ethanol / 12 h / 20 °C 2: hydrogenchloride / methanol / 12 h / 0 °C View Scheme

N-tert-butyloxycarbonylpiperidin-4-one (79099-07-3) → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: acetic acid; sodium tris(acetoxy)borohydride / dichloromethane / 16 h / 0 - 20 °C 2: hydrogenchloride / methanol / 12 h / 40 °C View Scheme

tert-butyl 4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
With hydrogenchloride In methanol at 40℃; for 12h;	0.826 g
With hydrogenchloride In methanol at 0℃; for 12h;

1-methyl-piperazine (109-01-3) → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: acetic acid; sodium tris(acetoxy)borohydride / dichloromethane / 16 h / 0 - 20 °C 2: hydrogenchloride / methanol / 12 h / 40 °C View Scheme
Multi-step reaction with 2 steps 1: sodium tris(acetoxy)borohydride; acetic acid / dichloromethane / 3 h / 20 °C 2: palladium on activated charcoal; hydrogen / methanol / 2 h / 20 °C / 3750.38 Torr View Scheme

1-phenylmethyl-4-piperidone (3612-20-2) → 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium tris(acetoxy)borohydride; acetic acid / dichloromethane / 3 h / 20 °C 2: palladium on activated charcoal; hydrogen / methanol / 2 h / 20 °C / 3750.38 Torr View Scheme

4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-carboxy-2-[3,5-dibromo-4-hydroxy-phenyl]-ethyl ester (866087-58-3) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(3,5-dibromo-4-hydroxy-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl ester

Conditions	Yield
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 3h;	99%

3-methoxy-4-nitrobenzoic acid (5081-36-7) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → (3-methoxy-4-nitrophenyl)(4-(4-methylpiperazin-1-yl)piperidin-1-yl)methanone

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃;	98%

1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester (868706-61-0)

Conditions	Yield
Stage #1: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-amino-3-methyl-5-nitro-phenyl)-1-carboxy-ethyl ester With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 1h; Stage #2: 1-methyl-4-(piperidin-4-yl)piperazine In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 4h; Stage #3: With sodium hydrogencarbonate In tetrahydrofuran; DMF (N,N-dimethyl-formamide); water	97%
Stage #1: 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-amino-3-methyl-5-nitro-phenyl)-1-carboxy-ethyl ester With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 1h; Stage #2: 1-methyl-4-(piperidin-4-yl)piperazine In tetrahydrofuran; DMF (N,N-dimethyl-formamide) at 20℃; for 4h;	97%

(R)-2-tert-butoxycarbonylamino-3-(3,4-diethyl-phenyl)-propionic acid (686297-85-8) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → {(R)-1-(3,4-diethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butylester (686297-90-5)

Conditions	Yield
With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃;	97%

4-fluoro-2-methoxy-1-nitrobenzene (448-19-1) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine (761440-65-7)

Conditions	Yield
With potassium carbonate In acetonitrile at 80℃; for 13h;	97%
With potassium carbonate In N,N-dimethyl-formamide at 120℃; for 18h; Time;	95%
With potassium carbonate In dichloromethane; N,N-dimethyl-formamide at 70℃;	90%

[4-(2-fluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (928038-12-4) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → N-(3-fluoro-4-{[2-({[2-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)clopropane-1,1-dicarboxamide

Conditions	Yield
In N,N-dimethyl-formamide at 20℃;	95%

[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetic acid (766558-33-2) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) + (2E)-but-2-enedioic acid (110-17-8) → 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulfonamide fumarate

Conditions	Yield
Stage #1: [2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetic acid; 1-methyl-4-(piperidin-4-yl)piperazine With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide at 20℃; for 20h; Stage #2: (2E)-but-2-enedioic acid	95%

1-fluoro-2-methoxy-4-nitrobenzene (454-16-0) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-(1-(2-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 80℃; for 15h;	95%
With potassium carbonate In acetonitrile at 60℃; for 2h; Inert atmosphere;	77.1%

ethyl 3-(1-methyl-1H-imidazol-2-yl)-3-oxopropanoate (1229426-30-5) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-(1-methyl-1H-imidazol-2-yl)-3-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)propan-1,3-dione

Conditions	Yield
With pyridine In toluene at 110℃; for 16h;	94%

1,2-difluoro-4-methoxy-5-nitro-benzene (66684-64-8) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-(1-(2-Fluoro-5-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine (1356963-21-7)

Conditions	Yield
Stage #1: 1,2-difluoro-4-methoxy-5-nitrobenzene; 1-methyl-4-(piperidin-4-yl)piperazine In dimethyl sulfoxide at 90℃; for 1h; Stage #2: With sodium hydrogencarbonate at 20℃;	90%

(R)-3-(4-amino-3,5-bis-trifluoromethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid (688021-04-7) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid {(R)-1-(4-amino-3,5-bis-trifluoromethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide

Conditions	Yield
Stage #1: (R)-3-(4-amino-3,5-bis-trifluoromethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid; 1-methyl-4-(piperidin-4-yl)piperazine With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In tetrahydrofuran at 20℃; Stage #2: With citric acid In water; ethyl acetate	89%

1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethoxy]ethyl]benzenesulphonamide

Conditions	Yield
Stage #1: [2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]acetic acid With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 0.5h; Stage #2: 1-methyl-4-(piperidin-4-yl)piperazine In dichloromethane at 20℃; for 18h;	86%

3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (911693-62-4) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 3-{8-(2,6-difluorophenyl)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran; chloroform at 20℃;	85%
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran; chloroform at 20℃;	85%

C14H18Br2N2O4 + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C24H37Br2N5O3

Conditions	Yield
With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide	83%

2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl)propanoic acid + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C22H33N5O

Conditions	Yield
Stage #1: 2-((tert-butoxycarbonyl)amino)-3-(1-methyl-1H-indol-3-yl)propanoic acid; 1-methyl-4-(piperidin-4-yl)piperazine With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In tetrahydrofuran Stage #2: With trifluoroacetic acid In dichloromethane	83%

1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(3-chloro-4-methyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl ester

Conditions	Yield
Stage #1: 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-carboxy-2-(3-chloro-4-methyl-phenyl)-ethyl ester With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In tetrahydrofuran at 20℃; for 1h; Stage #2: 1-methyl-4-(piperidin-4-yl)piperazine In tetrahydrofuran at 20℃;	83%

(4-bromophenyl)(trimethylsilyl)acetylene (16116-78-2) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-methyl-4-(1-{4-[(trimethylsilyl)ethynyl]phenyl}piperidin-4-yl)piperazine (1421580-70-2)

Conditions	Yield
With tris-(dibenzylideneacetone)dipalladium(0); lithium hexamethyldisilazane; DavePhos In tetrahydrofuran for 2h; Inert atmosphere; Reflux;	82%

(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-benzyloxy-propionic acid (1400766-00-8) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → (R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-benzyloxy-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-propan-1-one (688021-06-9)

Conditions	Yield
Stage #1: (R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-benzyloxy-propionic acid; 1-methyl-4-(piperidin-4-yl)piperazine With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In tetrahydrofuran at 20℃; Stage #2: With potassium carbonate In water; ethyl acetate Stage #3: With potassium carbonate; citric acid more than 3 stages;	81%

[4-(4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (928038-19-1) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → N-(4-Fluorophenyl)-N'-(4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide

Conditions	Yield
In N,N-dimethyl-formamide at 20℃;	79%

4-((5,11-dimethyl-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin2-yl)(methyl)amino)-3-methoxybenzoic acid + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)(methyl)amino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide for 15h;	78%

(S)-3-((S)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propanoyl)-4-phenyloxazolidin-2-one + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → (S)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)-1-(4-(4-methylpiperazine-1-yl)piperidin-1-yl)propan-1-one + (S)-4-phenyl-2-oxazolidinone (99395-88-7)

Conditions	Yield
With Trimethyl borate In toluene at 100℃; for 0.5h;	A 38% B 78%

C7H3(2)H3FNO3 + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C17H23(2)H3N4O3

Conditions	Yield
With potassium carbonate In acetonitrile at 60℃; for 2h; Inert atmosphere;	77.1%

Benzophenone imine (1013-88-3) + 2-bromo-5-chloroanisole (174913-09-8) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-1,1-diphenylmethanimine

Conditions	Yield
With allyl(2-di-tert-butylphosphino-2‘,4‘,6‘-triisopropyl-1,1‘-biphenyl)palladium(II) triflate; sodium t-butanolate; ruphos In tetrahydrofuran at 22 - 80℃; for 14h; Schlenk technique; Inert atmosphere; Sealed tube;	75%

6-chloro-3-nitro-2-(2,2,2-trifluoroethoxy)pyridine + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C17H24F3N5O3

Conditions	Yield
With potassium carbonate In acetonitrile at 80℃; Inert atmosphere;	74.9%

phenyl N-[4-(3-fluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]-N-phenoxycarbonylcarbamate (928038-09-9) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → N-(2-fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxyamide

Conditions	Yield
In N,N-dimethyl-formamide at 20℃; for 12h;	72.8%

4-fluoro-2-methoxy-5-nitro-phenylamine (1075705-01-9) + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-5-nitroaniline

Conditions	Yield
With potassium carbonate In acetonitrile at 85℃; for 24h;	72.5%

4-fluoro-2-[D3]methoxy-1-nitrobenzene + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → 1-(1-(3-[D3]methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide at 120℃; for 6h;	72%

Fmoc-D,L-tryptophan(t-Boc)-OH + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C26H39N5O3

Conditions	Yield
Stage #1: Fmoc-D,L-tryptophan(t-Boc)-OH; 1-methyl-4-(piperidin-4-yl)piperazine With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; Stage #2: With diethylamine at 20℃;	71%

N-[(1,1-dimethylethoxy)carbonyl]-3,5-dibromo-D-tyrosine + 1-methyl-4-(piperidin-4-yl)piperazine (53617-36-0) → C24H36Br2N4O4

Conditions	Yield
With benzotriazol-1-ol; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide	70%

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 109-01-3 1-methyl-piperazine 
• 190964-91-1 tert-butyl 4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 868706-61-0 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-(4-amino-3-methyl-5-nitro-benzyl)-2-[4-(4-methyl-piperazin-1-yl)piperidin-1-yl]-2-oxo-ethyl ester 
• 686297-90-5 {(R)-1-(3,4-diethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butylester 
• 688020-57-7 (S)-3-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-oxo-butanoic acid tert-butyl ester 
• 688021-06-9 (R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-benzyloxy-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-propan-1-one 
• 1238312-25-8 C₃₁H₃₃F₆N₉O 
• 1356963-21-7 1-(1-(2-Fluoro-5-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine 

Relevant academic research and scientific papers

ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

2-amino-4-substituted pyridine derivative as well as synthesis method and application thereof

The invention discloses a 2-amino-4-substituted pyridine derivative as well as a synthesis method and an application thereof. The derivative with the structural formula is a compound with the structure or pharmacologically acceptable salt, hydrate, solvate, polymorphic substance, tautomer, stereoisomer, isotope derivative or prodrug of the compound. The 2-amino-4-substituted pyridine derivative has higher EGFR (epidermal growth factor receptor) inhibition activity, has higher inhibition activity for human epidermal cell carcinoma cells, glioblastoma cells and the like and can be used for preparing drugs for treating and/or preventing and/or delaying and/or assisting in treatment and/or treatment of diseases related with too high EGFR activity.

CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

An object of the present invention is to provide a compound exerting an analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine derivative represented by the following general formula, or a pharmacologically acceptable salt thereof.

CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.

Cyclic amine derivative and pharmaceutical use thereof

The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine derivative represented by chemical formula, a prodrug thereof or a pharmaceutically acceptable salt thereof.

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.